| 33.875 -0.145 (-0.43%) | 06-26 15:33 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 40.5 | 1-year : | 47.31 |
| Resists | First : | 34.68 | Second : | 40.5 |
| Pivot price | 30.84 |
|||
| Supports | First : | 30.5 | Second : | 27.92 |
| MAs | MA(5) : | 33.05 |
MA(20) : | 30.41 |
| MA(100) : | 28.58 |
MA(250) : | 21.58 |
|
| MACD | MACD : | 1.1 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 89.3 |
D(3) : | 88.6 |
| RSI | RSI(14): 70.4 |
|||
| 52-week | High : | 34.68 | Low : | 10.7 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ROIV ] has closed below upper band by 11.0%. Bollinger Bands are 87.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 34.72 - 34.86 | 34.86 - 34.99 |
| Low: | 33.52 - 33.68 | 33.68 - 33.84 |
| Close: | 33.76 - 34.01 | 34.01 - 34.25 |
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Thu, 25 Jun 2026
Price to book forward of Roivant Sciences Ltd. – NASDAQ:ROIV - TradingView
Thu, 25 Jun 2026
Morgan Stanley Smith Barney files 500,000-share sale (NASDAQ: ROIV) - Stock Titan
Wed, 24 Jun 2026
Roivant Sciences Ltd (ROIV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Mon, 22 Jun 2026
Roivant Sciences Ltd. (ROIV) Stock Analysis: Navigating Biotech Opportunities with 24.22% Potential Upside - DirectorsTalk Interviews
Sat, 20 Jun 2026
What Roivant Sciences (ROIV)'s $2.25 Billion Moderna Settlement and Immunology Wins Mean For Shareholders - Sahm
Tue, 09 Jun 2026
Guggenheim Remains Bullish on Roivant Sciences Ltd. (ROIV) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 719 (M) |
| Held by Insiders | 5.4551e+008 (%) |
| Held by Institutions | 23.3 (%) |
| Shares Short | 27,060 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.28e+009 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -14 % |
| Return on Assets (ttm) | 675 % |
| Return on Equity (ttm) | -14.4 % |
| Qtrly Rev. Growth | 8.26e+006 % |
| Gross Profit (p.s.) | -58.51 |
| Sales Per Share | -6.66 |
| EBITDA (p.s.) | -5.91175e+008 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -750 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -5.08 |
| Price to Cash Flow | 6.4 |
| Dividend | 0 |
| Forward Dividend | 3.623e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|